|Bid||11.30 x 100|
|Ask||11.90 x 2000|
|Day's Range||11.29 - 11.85|
|52 Week Range||4.10 - 15.35|
|PE Ratio (TTM)||-6.06|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||24.50|
NEW YORK, Sept. 21, 2017-- TG Therapeutics, Inc. today announced its participation at two upcoming investor conferences. Michael S. Weiss, the Company’ s Executive Chairman and Chief Executive Officer, ...
NEW YORK, Sept. 15, 2017-- TG Therapeutics, Inc. today announced that enrollment is now open for the Phase 3 ULTIMATE I and II trials. ULTIMATE I and II are two independent Phase 3 clinical trials evaluating ...
TG Therapeutics Inc (NASDAQ:TGTX), a pharmaceuticals, biotechnology and life sciences company based in United States, View our latest analysis for TG Therapeutics Is TGTX still cheap? The stock seems fairlyRead More...